Prof. Michael Albeck

עברית Tell a Friend
Telephone
Email
Michael.Albeck@biu.ac.il
Office
Bldg. 211, Room 111. albeck.biomas@gmail.com
Research Categories
CV

Born: 1934

 

Education:

1959: MSc, Chemistry, The Hebrew University, Jerusalem

1962: PhD, Chemistry, The Hebrew University, Jerusalem

Appointments:

1962-1964: Principal Investigator, The Institute for Fiber and Forest Products, Jerusalem

1964-1965: Head of the chemical laboratories, Mekorot Water Company

1965-2003: faculty member (full Prof. Since 1978), Department of Chemistry, Bar Ilan University

2003-        : Professor Emeritus, Bar Ilan University

Academic and scientific activities:

At Bar Ilan

1967-1969: Dean, Faculty of Natural Sciences

1972-1975: Dean, Faculty of Natural Sciences

1982-1999: member, Board of Governors and Board of Trustees

1982-1986: Rector of the university

1986-1989: President of the university

Outside Bar Ilan

member of the boards: The Weizmann Scientific Press, Dead Sea Works, The German-Israel Binational Foundation (GIF), Teva Pharmaceuticals 

President, The Israel Chemical Society.
 

Research

The chemistry, biological activity and therapeutic applications of organic and inorganic tellurium compounds.

Projects:

Synthesis of inorganic tellurium compounds such as AS-101 and SAS, and of organic tellurium compounds 

Mechanisms of interaction of inorganic tellurium compounds with their environment and biological targets

The immunomodulatory effects of AS-101 and SAS

Therapeutic applications of AS-101 and SAS

 

Publications

מאמרים מייצגים ״ישנים״:

Nature 1987330, 173

Synthesis 19898, 635

Nat Immun Cell Growth Regul 19909, 182

Cancer Res 199151, 1499

Nat Immunol 199312, 50

Inorg Chem 199837, 1904

J Neurochem 200385, 90

 

10 שנים אחרונות:

The immunomodulator, ammonium trichloro[1,2-ethanediolato-O,O]-tellurate, suppresses the propagation of herpes simplex virus 2 by reducing the infectivity of the virus progeny. International Journal of Molecular Medicine  2015, 36, 231-238.

Sensitizing B- and T- cell Lymphoma Cells to Paclitaxel/Abraxane-Induced Death by AS101 via Inhibition of the VLA-4-IL10-Survivin Axis. Molecular Cancer Research 2015, 13, 411-422.

Multifunctional Activity of a Small Tellurium Redox Immunomodulator Compound, AS101, on Dextran Sodium Sulfate-induced Murine Colitis. Journal of Biological Chemistry 2014, 289, 17215-17227.

Redox Modulation of Adjacent Thiols in VLA-4 by AS101 Converts Myeloid Leukemia Cells from a Drug-Resistant to Drug-Sensitive State. Cancer Research 2014, 74, 3092-3103.

In vitro and in vivo activity of AS101 against West Nile virus (WNV). Virus Research 2012, 166, 68-76.

The anti-inflammatory effects of the tellurium redox modulating compound, AS101, are associated with regulation of NF kappa B signaling pathway and nitric oxide induction in macrophages. Journal of Inflammation-London 2010, 7, Article Number: 3.

Resolution of inflammation-related apoptotic processes by the synthetic tellurium compound, AS101 following liver injury. Journal of Hepatology 2009, 51, 491-503.

A potential antimicrobial treatment against ESBL-producing Klebsiella pneumoniae using the tellurium compound AS101. Archives of Microbiology 2009, 191, 631-638.

The cyclin kinase inhibitor p57(kip2) regulates TGF-beta-induced compensatory tubular hypertrophy: effect of the immunomodulator AS101. Nephrology Dialysis Transplantation 2009, 24, 2328-2338.

Protective effect of the immunomodulator AS101 against cyclophosphamide-induced testicular damage in mice. Human Reproduction 2009, 24, 1322-1329.

Induction therapy in a multiple myeloma mouse model using a combination of AS101 and melphalan, and the activity of AS101 in a tumor microenvironment model. Experimental Hematology 2009, 37, 593-603.

Topical treatment for human papillomavirus-associated genital warts in humans with the novel tellurium immunomodulator AS101: assessment of its safety and efficacy. British Journal of Dermatology 2009, 160, 403-408.

Antitumour effects in mycosis fungoides of the immunomodulatory, tellurium-based compound, AS101. British Journal of Dermatology 2008, 158, 578-586.

Octa-O-bis-(R,R)-tartarate ditellurane (SAS) - a novel bioactive organotellurium(IV) compound: Synthesis, characterization, and protease inhibitory activity. ChemMedChem 2007, 2, 1601-1606.

Neutral and positively charged thiols synergize the effect of the immunomodulator AS101 as a growth inhibitor of Jurkat cells, by increasing its uptake. Biochemical Pharmacology 2007, 74, 712-722.

The organotellurium compound ammonium trichloro(dioxoethylene-0,0') tellurate enhances neuronal survival and improves functional outcome in an ischemic stroke model in mice. Journal of Neurochemistry 2007, 102, 1232-1241.

The organotellurium compound ammonium trichloro(dioxoethylene-o,o ')tellurate reacts with homocysteine to form homocystine and decreases homocysteine levels in hyperhomocysteinemic mice. FEBS Journal 2007, 274, 3159-3170.

Synergistic effect of AS101 and Bryostatin-1 on myeloid leukemia cell differentiation in vitro and in an animal model. Leukemia 2007, 21, 1504-1513.

Multifunctional tellurium molecule protects and restores dopaminergic neurons in Parkinson's disease models. FASEB Journal  2007, 21, 1870-1883.

The synthetic tellurium compound, AS101, is a novel inhibitor of IL-1 beta converting enzyme. Journal of Interferon and Cytokine Research 2007, 27, 453-462.